22:23 , Feb 2, 2018 |  BioCentury  |  Product Development

Local advantage

Theravance Biopharma Inc. is reaching a key inflection point for the first candidate to emerge from its program to develop me-better immunology therapies that act locally and avoid systemic side effects. The company will report...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Clinical News

Velusetrag: Phase II data

The double-blind, 3-way crossover Phase II Study 0093 trial in 34 patients with diabetic or idiopathic gastroparesis showed that once-daily oral velusetrag for 1 week reduced gastric emptying half-time by 35 minutes at the 5...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

Xifaxan rifaximin regulatory update

FDA approved an sNDA for Xifaxan rifaximin 550 mg tablets from Valeant to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. Valeant said the non-aminoglycoside, semi-synthetic antibiotic derived from rifamycin SV is the first...
07:00 , Apr 6, 2015 |  BioCentury  |  Finance

Q is for quiet

Investors expect 2Q15 to be fairly quiet in terms of news flow until the deluge of data for cancer immunotherapy combinations come out in June at the American Society of Clinical Oncology meeting. The problem...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Company News

Alfa Wassermann, Norgine sales and marketing update

The U.K.’s NICE issued final guidance recommending 550 mg Targaxan rifaximin from Norgine to prevent recurrence of episodes of overt hepatic encephalopathy (HE) in adults -- its approved indication in the EU. The guidance...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

Velusetrag: Phase IIb started

Theravance began the double-blind, placebo-controlled, international Phase IIb Study 0099 to evaluate 5, 15 and 30 mg oral velusetrag once daily for 12 weeks in about 200 patients with diabetic or idiopathic gastroparesis. In 2012,...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Clinical News

Targaxan rifaximin regulatory update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending 550 mg Targaxan rifaximin from Norgine to prevent recurrence of episodes of overt hepatic encephalopathy (HE) in adults -- its approved indication in the EU....
08:00 , Nov 10, 2014 |  BC Week In Review  |  Company News

Salix, Lupin deal

Salix granted Lupin exclusive rights to market Zaxine rifaximin 550 mg and subcutaneous Relistor methylnaltrexone in Canada. In Canada, Zaxine is approved to reduce the risk of overt hepatic encephalopathy (HE) recurrence in adult...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Company News

Cipla, Salix deal

Cipla granted Salix exclusive, worldwide rights excluding Africa and Asia, but including Japan, to patent applications covering rifaximin complexes. Cipla will receive an undisclosed upfront payment and is eligible to receive milestones and royalties. Additionally,...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Clinical News

Xifaxan rifaximin: Additional Phase III data

Additional data from the double-blind, international Phase III TARGET 3 trial in 636 patients with IBS-D showed that retreatment with thrice-daily 550 mg oral Xifaxan met the secondary composite endpoint of a greater proportion of...